Phosphorylation of the Smad1 linker domain, which was partially regulated by Smad3 signaling, attenuated glomerulosclerosis, suggesting that Smad1 linker domain can be used as a target for treating DN. This evidence concerns the gene SMAD1 and glomerulosclerosis.